Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Validate GMU's Protein Biomarkers

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will work with researchers at George Mason University to validate protein biomarkers GMU discovered using Thermo Fisher’s mass spectrometry technology.
 
Scientists at GMU’s Center for Applied Proteomics and Molecular Medicine (CAPMM) will use Thermo Fisher’s Quantum Ultra triple quadrupole mass spectrometers to discover cancer biomarkers, which the company will cross-validate at its Biomarker Research Initiatives in Mass Spectrometry Center.
 
"We're focused on developing a robust, reproducible protein biomarker analytical workflow that could shave years off the process of translating biomarkers into validated clinical diagnostic laboratory tests," Emanuel Petricoin, who chairs GMU’s Department of Molecular and Microbiology, said in a statement.
 

CAPMM Co-director Lance Liotta called the processes of validating and verifying biomarkers “the chief bottlenecks in the entire research community,” and he said this collaboration could help to “ease, if not possibly eliminate, this challenge all together.”

 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.